{"id":"iopofosine-i-131-single-dose","safety":{"commonSideEffects":[{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL4297495","moleculeType":"Small molecule","molecularWeight":"641.63"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Iopofosine I 131 is a targeted alpha-particle therapy that utilizes a phospholipid-drug conjugate to selectively accumulate in cancer cells, where it emits alpha particles to induce cell death. This approach allows for a high dose of radiation to be delivered directly to the tumor site while minimizing exposure to surrounding healthy tissues.","oneSentence":"Iopofosine I 131 is a phospholipid-drug conjugate that selectively targets and accumulates in cancer cells, allowing for targeted radiation therapy.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:56:02.812Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory peripheral T-cell lymphoma"}]},"trialDetails":[{"nctId":"NCT02952508","phase":"PHASE2","title":"Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cellectar Biosciences, Inc.","startDate":"2017-07-26","conditions":"Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["I-131-CLR1404","CLR 131"],"phase":"phase_2","status":"active","brandName":"Iopofosine I 131 single dose","genericName":"Iopofosine I 131 single dose","companyName":"Cellectar Biosciences, Inc.","companyId":"cellectar-biosciences-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Iopofosine I 131 is a phospholipid-drug conjugate that selectively targets and accumulates in cancer cells, allowing for targeted radiation therapy. Used for Relapsed or refractory peripheral T-cell lymphoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}